• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 16, 2024 at 12:02: PM
via Biogen’s CEO may have been celebrating “turning a corner” last month, but it looks like the drugmaker’s early-stage pipeline hasn’t gotten the message yet.

The Cambridge, Massachusetts-based company announced this morning that it is halting its work on Ionis Pharmaceuticals-partnered oligonucleotides for two different diseases. That includes the amyotrophic lateral sclerosis (ALS) drug BIIB105, which was designed to reduce expression of the ATXN2 gene.

article source
 




Top Bottom
Back
Quote